Is Zepbound Covered by Medicaid in 2026? State-by-State Coverage Rules

Reviewed by FormBlends Medical Team · Corrected and updated September 5, 2026 · sources listed below

Key Takeaways

• Medicaid Zepbound coverage depends on your state. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in October 2025, and MassHealth ended coverage on July 1, 2026 (KFF, January 16, 2026; WBUR, June 23, 2026)
• Every state Medicaid program covers tirzepatide as Mounjaro for type 2 diabetes, an FDA-approved use, usually with prior authorization; Zepbound for obesity is the optional benefit, and a few states (West Virginia, Louisiana) cover Zepbound only for sleep apnea
• Correction, September 2026: earlier versions of this page gave an 18/23/9 state breakdown, a 34% approval rate, a 41% appeal rate, an HHS OIG audit and a bill called the Anti-Obesity Medication Access Act. None of those could be verified and all have been removed
• Compounded tirzepatide requires no prior authorization and is not covered by Medicaid; see the current price on the product page and in our price index (market median month-1 price $299 as of September 3, 2026)

The short answer

Zepbound coverage under Medicaid varies by state. As of September 5, 2026, the most recent national count is KFF's: 13 state Medicaid fee-for-service programs covered GLP-1s for obesity treatment in January 2026, after California, New Hampshire, Pennsylvania and South Carolina dropped the benefit. Massachusetts followed on July 1, 2026. Every state covers tirzepatide for type 2 diabetes (as Mounjaro), because federal law lets states exclude drugs "when used for anorexia, weight loss, or weight gain" but not drugs for diabetes. Coverage decisions for the obesity indication are made state by state, and 2026 has mostly seen states leaving.

Table of contents

1. The state-by-state coverage map
2. Why Medicaid treats Zepbound differently than commercial insurance
3. The three coverage categories explained
4. Prior authorization requirements in states that cover Zepbound
5. What most articles get wrong about Medicaid obesity drug coverage
6. The off-label diabetes pathway (and why providers use it)
7. The 2026 federal legislation that could change everything
8. Real denial scenarios and appeal success rates
9. The compounded tirzepatide alternative for Medicaid patients
10. How to verify your state's specific Zepbound policy in 10 minutes
11. When Medicaid patients should NOT pursue Zepbound coverage
12. Medicare vs Medicaid in 2026
13. Self-pay reality check (dated)
14. FAQ

The state-by-state coverage map

Correction, September 2026: an earlier version of this section sorted states into three named categories with an 18-state list of programs "covering Zepbound for weight management," a 23-state "off-label diabetes" list and a 9-state "statutory exclusion" list. Those lists could not be reconciled with any primary source: California and Massachusetts appeared as covering states after both had announced an end to coverage, Mounjaro for diabetes was mislabeled as off-label, and West Virginia and Wisconsin were listed as excluding when each covers at least one GLP-1 for a non-diabetes indication. The lists have been removed.

What can be documented, with dates:

State	Status of Zepbound (or other GLP-1) for obesity	Effective	Source
National count	13 fee-for-service programs covered GLP-1s for obesity (16 in October 2025)	January 2026	KFF, January 16, 2026
California (Medi-Cal Rx)	No longer covers Saxenda, Wegovy or Zepbound for weight loss; still covered with PA for FDA-approved uses such as type 2 diabetes, cardiovascular disease and kidney disease; EPSDT exception for children	January 1, 2026	Medi-Cal Rx bulletin, October 21, 2025
Pennsylvania	Ended GLP-1 coverage for weight loss in adults 21 and older; under-21 (EPSDT) and other FDA indications continue	January 1, 2026	Pennsylvania Health Law Project, December 22, 2025
North Carolina	Stopped covering Wegovy and Zepbound solely for obesity on October 1, 2025 (other indications kept); KFF reports obesity coverage was reinstated in December 2025	October 1 and December 2025	NC Medicaid, November 4, 2025; KFF
Michigan	Coverage of Wegovy, Zepbound and Saxenda "when prescribed solely to treat obesity" reduced to narrower criteria (morbid obesity, failed alternatives); existing approvals honored for their 6-month term	January 1, 2026	Meridian provider bulletin, December 16, 2025
Massachusetts (MassHealth)	Ended GLP-1 coverage for weight loss (about 22,000 members); coverage continues for type 2 diabetes, sleep apnea with obesity, MASH and cardiovascular risk reduction	July 1, 2026	WBUR, June 23, 2026
West Virginia	Weight-loss agents are a benefit exclusion; Zepbound covered only for obstructive sleep apnea in adults with obesity	July 1, 2025	WV Bureau for Medical Services PA criteria
Louisiana	Zepbound criteria cover adults 18 and older with moderate-to-severe sleep apnea and BMI 30 or more, without diabetes; 6-month approvals	June 5, 2025	Louisiana Department of Health criteria

KFF's 13-state figure is published as a map rather than a list, and a secondary aggregator (glpchart.com, August 28, 2026) counts 20 programs covering Wegovy or Zepbound for weight loss but conflicts with the state bulletins above for California, New Hampshire and Pennsylvania. Treat any state list, including ours, as a starting point and confirm against your state's current preferred drug list.

Why Medicaid treats Zepbound differently than commercial insurance

The federal Medicaid statute contains a specific carve-out. Under 42 U.S.C. § 1396r-8(d)(2), states may exclude "agents when used for anorexia, weight loss, or weight gain" from their Medicaid drug formularies.

This carve-out dates to the Omnibus Budget Reconciliation Act of 1990, which created the Medicaid drug rebate statute; the text of 42 U.S.C. 1396r-8(d)(2)(A) permits states to exclude "agents when used for anorexia, weight loss, or weight gain." It was written when weight-loss drugs were mostly stimulants and has not been updated for GLP-1 receptor agonists, which have cardiovascular benefits beyond weight: the SELECT trial of semaglutide 2.4 mg (Lincoff et al., NEJM 2023) is the outcomes trial usually cited. Correction, September 2026: an earlier version dated the statute to 1993 and attributed the SELECT result to tirzepatide.

Commercial insurance plans are not bound by this statute. Private plans follow their own medical policies, which vary widely and have tightened in 2026. Correction, September 2026: an earlier version quoted a "72% of employer plans" figure from a 2025 survey; we could not access the survey to confirm a 2026 value and have removed the number.

The coverage gap creates a two-tier system. A patient with employer insurance and BMI 32 may get Zepbound covered, with a manufacturer savings card bringing the copay to as little as $25 a month (Lilly, 2026 program). The same patient on Medicaid in a state that has dropped the obesity benefit gets no coverage. The clinical need is identical. The coverage is not.

The three coverage categories explained

Correction, September 2026: the three-category framework that used to fill this section has been retired because its state assignments were wrong. What follows is what the documents actually show.

What "covered" means. Coverage does not mean automatic approval. It means Zepbound is on the state's preferred drug list for the obesity indication and eligible for reimbursement if prior authorization criteria are met. Published criteria from states that do cover a GLP-1 for a non-diabetes indication look like this (Louisiana Zepbound criteria, June 5, 2025; West Virginia criteria effective July 1, 2025):

• Adults 18 and older with a qualifying diagnosis (in Louisiana and West Virginia, moderate-to-severe obstructive sleep apnea, defined by an apnea-hypopnea index of 15 or more, in adults with obesity)
• BMI of 30 or more
• No type 1 or type 2 diabetes (tirzepatide for diabetes is covered separately as Mounjaro)
• Use as an adjunct to a reduced-calorie diet and increased physical activity
• Initial approval for 6 months; continuation requires at least 5% weight loss

Michigan's narrowed 2026 criteria add morbid obesity and documented failure of alternatives. No state or federal source publishes first-submission approval rates for Zepbound; a "34%" figure that used to appear here had no source.

The diabetes indication is on-label everywhere. Tirzepatide sold as Mounjaro is FDA-approved for type 2 diabetes and covered by every state Medicaid program, generally with prior authorization. An earlier version of this page called that "off-label diabetes use"; it is not. The medications are the same molecule, but the prescription must match a real diagnosis. Writing a diabetes diagnosis that a patient does not have to obtain coverage is fraud. Correction, September 2026: an earlier version cited an "HHS OIG report" finding 11% of tirzepatide claims lacked a diabetes code; no such report exists and it has been removed.

States that have left. The 2026 pattern is states ending or narrowing the obesity benefit for budget reasons: California and Pennsylvania (adults) on January 1, 2026; Michigan narrowed on the same date; Massachusetts on July 1, 2026. Each kept coverage for FDA-approved indications other than weight loss. Enrollment counts that used to appear here for Texas and Pennsylvania were unsourced and have been removed.

Prior authorization requirements in states that cover Zepbound

Prior authorization is the gatekeeper. Even in states that cover Zepbound, PA denial is more common than approval on first submission.

Common documentation gaps

Correction, September 2026: an earlier version presented these as a FormBlends "clinical observation" appearing in "80% of denials." We have no published dataset behind that figure and have removed it. The three gaps below are the ones state criteria documents make explicit:

1. Insufficient behavioral intervention documentation. The PA form asks for "documented failure of diet and exercise." Providers often write "patient reports trying Weight Watchers." Medicaid wants dated progress notes, dietitian visits, or structured program enrollment records. A single sentence doesn't meet the threshold.

1. Missing comorbidity ICD-10 codes. The patient has hypertension and prediabetes, but the prescription lists only E66.9 (obesity, unspecified). Medicaid's automated PA system doesn't see the comorbidities because they're not on the prescription. Adding I10 (hypertension) and R73.03 (prediabetes) to the Rx increases approval odds significantly.

1. Wrong prescriber type. Some state Medicaid programs restrict GLP-1 prescribing to endocrinologists or bariatric specialists. A family medicine NP's prescription gets auto-denied even if everything else is correct. The patient doesn't know to ask their PCP to refer to an endocrinologist for the prescription.

These aren't clinical failures. They're administrative formatting errors. But they result in the same outcome: denial and a 30-day appeal window.

Standard PA turnaround time

Federal Medicaid managed care rules set outer limits for prior authorization decisions (expedited requests within 72 hours, standard requests within 14 calendar days). No source publishes an average turnaround for Zepbound specifically; a "9 to 12 days" average that used to appear here has been removed.

If the PA is denied, the patient has 30 to 60 days to appeal (varies by state). The appeal requires the prescriber to submit additional documentation addressing the specific denial reason. Second-level appeals go to an independent medical reviewer.

No drug-specific appeal success rate is published by any state, CMS or MACPAC. Correction, September 2026: a "41%" appeal rate attributed to MACPAC has been removed. Successful appeals generally add the documentation the criteria asked for rather than argue with the criteria.

What most articles get wrong about Medicaid obesity drug coverage

Most coverage summaries claim "Medicaid doesn't cover weight-loss drugs." This is imprecise and outdated.

The error: Conflating federal law with state implementation.

Federal law permits states to exclude weight-loss medications. It does not require exclusion. As of January 2026, KFF counted 13 state programs that chose to cover GLP-1s for obesity under fee-for-service, roughly a quarter of programs, and the number has fallen since.

The accurate statement: "Medicaid coverage for Zepbound depends on your state. Some states cover it with prior authorization, some cover it only for diabetes, and some exclude it entirely."

Why the error persists: Most articles cite the 1990 federal statute (42 U.S.C. 1396r-8) and stop there. They don't check current state formularies, which change quarterly and in 2026 have changed mostly in one direction. As a result, patients in a state that still covers the obesity indication may never submit a PA, while patients in California or Massachusetts may still be citing coverage that ended.

The correction: Check your specific state's Medicaid PDL. Every state publishes its preferred drug list online, updated quarterly. Search for "tirzepatide" or "Zepbound." If it's listed, coverage is possible. If it's not listed, coverage requires either an off-label diabetes indication or an out-of-pocket alternative.

KFF publishes periodic analyses of state Medicaid GLP-1 coverage; the most recent national count (January 16, 2026) found 13 fee-for-service programs covering the obesity indication. KFF is the most reliable public source for the count, but it is not updated monthly and does not publish a text list, so the state's own preferred drug list is the final word.

The off-label diabetes pathway (and why providers use it)

Tirzepatide is FDA-approved for two indications:

• Type 2 diabetes (marketed as Mounjaro)
• Chronic weight management (marketed as Zepbound)

The drug is identical. The dosing is identical. The difference is the indication on the prescription and the brand name on the box.

In states that do not cover the obesity indication, Medicaid still covers Mounjaro for type 2 diabetes with prior authorization. Some providers prescribe tirzepatide for patients with obesity and prediabetes, metabolic syndrome, or fatty liver disease, framing the prescription as diabetes prevention.

Is this legal?

Yes. Off-label prescribing is legal and common. The FDA regulates drug approval and marketing, not physician prescribing. A provider can prescribe any FDA-approved medication for any condition if they believe it's medically appropriate.

Is this compliant with Medicaid rules?

Gray area. Medicaid requires that prescriptions be medically necessary for a covered indication. If the patient has documented prediabetes (A1C 5.7% to 6.4%) and the provider documents diabetes prevention as the treatment goal, the prescription is defensible.

If the patient has no diabetes or prediabetes and the provider writes "type 2 diabetes" on the prescription purely to obtain coverage, that's fraud.

What happens in practice?

Correction, September 2026: an earlier version described audit thresholds (how many prescriptions per month would or would not trigger review). Those figures were invented and have been removed; state Medicaid programs do not publish audit triggers.

The risk is retrospective recoupment. If an audit finds that a prescription was not medically necessary for the documented indication, Medicaid can demand repayment from the pharmacy or provider. The patient is not usually liable, but the provider may stop prescribing to avoid future audits.

This is why many providers in non-covering states decline to prescribe tirzepatide for obesity through Medicaid, even where a prediabetes argument could be made. The compliance risk outweighs the clinical benefit.

The 2026 federal legislation that could change everything

The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2013. It has never passed.

Correction, September 2026: an earlier version of this section gave the wrong bill numbers, described a Medicaid coverage mandate that is not in the bill, cited a "March 2026" CBO score that does not exist, and quoted cosponsor counts we could not verify. It also referred in the Key Takeaways to an "Anti-Obesity Medication Access Act," a bill we could not find. Here is what the record shows as of September 5, 2026.

The current version is the Treat and Reduce Obesity Act of 2025, H.R. 4231, introduced June 27, 2025 by Representative Mike Kelly, with a Senate companion, S. 1973. Its provisions concern Medicare: allowing Part D to cover anti-obesity medications (currently excluded by statute) and expanding Medicare coverage of intensive behavioral therapy for obesity. It does not require state Medicaid programs to cover GLP-1s for obesity.

What the CBO actually estimated: In October 2024 (publication 60441) the Congressional Budget Office estimated that Medicare coverage of anti-obesity medications would raise federal spending by about $35 billion net from 2026 through 2034. That is a Medicare estimate. There is no CBO score of a Medicaid mandate, and the "$18 billion" state cost that used to appear here was invented.

Cardiovascular evidence cited by proponents: the SELECT trial (Lincoff et al., NEJM 2023) found semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes. It is a semaglutide trial, not a tirzepatide trial.

What has actually changed in 2026 is on the executive side, not in Congress. The Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) lets Medicare Part D enrollees get Wegovy, Zepbound KwikPen or Foundayo for a $50 monthly copay with prior authorization, outside the $2,100 out-of-pocket cap. For Medicaid, CMS's BALANCE model is voluntary for states, with rolling implementation from May 1, 2026 to January 1, 2027 and a state application deadline of July 31, 2026 (KFF, May 11, 2026). Neither is a mandate, and neither reverses the 2026 state exits described above.

Real denial scenarios and appeal success rates

Correction, September 2026: this section previously walked through five illustrative patient scenarios and an "appeal success rate" of 41%. Two of the scenarios were set in states whose rules had changed (California ended Zepbound coverage for weight loss on January 1, 2026; Illinois could not be verified), one described a fraudulent resubmission, and the appeal rate had no source. All have been removed. In their place, the documented rules that decide most requests:

• Louisiana (criteria dated June 5, 2025): Zepbound approved for adults 18 and older with moderate-to-severe obstructive sleep apnea (AHI 15 or more) and BMI 30 or more, without diabetes, as an adjunct to lifestyle change; 6-month approvals; continuation requires at least 5% weight loss.
• West Virginia (effective July 1, 2025): weight-loss agents are a benefit exclusion; Zepbound is considered only for a diagnosis of OSA in adults with obesity.
• Michigan (effective January 1, 2026): Wegovy, Zepbound and Saxenda for obesity alone limited to morbid obesity with failed alternatives; prior approvals honored through their 6-month term.
• California, Pennsylvania (adults), Massachusetts: no coverage for weight loss as of January 1, 2026, January 1, 2026 and July 1, 2026 respectively; other FDA indications still covered with PA.

Appeals that succeed generally supply the specific document the criteria asked for (a sleep study, a dated weight history, a diabetes exclusion). Arguing that the criteria themselves are too strict almost never works at the plan level.

The compounded tirzepatide alternative for Medicaid patients

For patients whose state does not cover the obesity indication, or whose prior authorization is denied, compounded tirzepatide is the most common alternative, followed by Lilly's own self-pay channel.

Pricing comparison:

Prices as of September 5, 2026 (Lilly) and September 3, 2026 (the Compounded GLP-1 Price Index). Correction, September 2026: an earlier version listed brand Zepbound at "$1,060 to $1,350" cash and compounded tirzepatide at "$179 to $279"; neither matched current published prices.

Option	Monthly cost	Insurance required?	PA required?
Brand Zepbound (Medicaid covered)	State copay, typically small or none	Yes	Yes
Brand Zepbound, LillyDirect self-pay vial or KwikPen	$299 (2.5 mg), $399 (5 mg), $449 (7.5 mg and up) if refilled within 45 days; otherwise $499 to $699	No	No
Brand Zepbound, commercial insurance that excludes it (savings card)	$499	Yes (commercial, not Medicaid)	No
Brand Zepbound, commercial insurance that covers it (savings card)	As low as $25; monthly caps $100 to $300, $1,300 a year, 13 fills, through December 31, 2026	Yes (commercial, not Medicaid)	Usually
Compounded tirzepatide (FormBlends)	Current price on the product page and in our price index	No	No
Compounded tirzepatide (market)	Median month-1 price $299 across 14 vendors tracked in the price index, September 3, 2026	No	No

Medicaid and Medicare patients are not eligible for the Lilly savings card; LillyDirect self-pay is open to anyone paying cash.

Key differences:

Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's drawn from a vial with a syringe rather than delivered in a pre-filled pen.

The active ingredient (tirzepatide) is the same. The delivery mechanism and quality oversight differ.

When compounded makes sense for Medicaid patients:

• Your state does not cover Zepbound for obesity
• Your PA was denied and your appeal failed
• You don't have diabetes, so the Mounjaro pathway does not apply to you
• You need treatment now and can't wait 14 days for PA processing
• You prefer predictable monthly pricing without insurance paperwork

When brand Zepbound makes more sense:

• Your state covers the obesity indication and you meet its PA criteria
• You have a provider willing to submit and manage PA/appeals
• You prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your state Medicaid copay is small or zero

The decision depends on your state, your PA status, and your tolerance for the compounded vs. brand-name trade-off. A licensed provider should walk through both options before you start either treatment.

How to verify your state's specific Zepbound policy in 10 minutes

Step 1: Find your state Medicaid formulary

Google "[your state] Medicaid preferred drug list" or "[your state] Medicaid PDL." Every state publishes its formulary online, usually as a searchable PDF or database.

Step 2: Search for tirzepatide or Zepbound

Use Ctrl+F to search the PDL for "tirzepatide" or "Zepbound." If Zepbound appears with obesity or weight-management criteria, the obesity indication is covered with PA. If only Mounjaro appears, your state covers tirzepatide for diabetes only. Some states list Zepbound only under sleep apnea criteria.

Step 3: Check the PA criteria

Most PDLs link to prior authorization forms or criteria documents. Download the PA form for tirzepatide. Read the required documentation. Common requirements include BMI threshold, comorbidities, prior behavioral interventions, and prescriber qualifications.

Step 4: Call your Medicaid managed care plan

If you're enrolled in a Medicaid managed care plan (most states use managed care), call the member services number on your card. Ask: "Does my plan cover Zepbound for weight management? What are the prior authorization requirements?"

The plan's formulary may differ slightly from the state PDL. Managed care plans can impose additional restrictions beyond state minimums.

Step 5: Verify with your provider

Bring the PA form to your provider. Ask: "Can you submit this PA for me? Do I meet the criteria?" Your provider sees PA approvals and denials across many patients and can estimate your likelihood of approval.

This 10-minute verification prevents the most common surprise: assuming you're not covered when you actually are, or assuming you're covered when your state excludes weight-loss drugs entirely.

When Medicaid patients should NOT pursue Zepbound coverage

Situation 1: Your state doesn't cover the obesity indication and your provider suggests fraudulent coding

If your provider offers to write "type 2 diabetes" on your prescription when you don't have diabetes, decline. This is fraud. It exposes your provider to criminal liability and you to potential Medicaid termination.

The compounded alternative is legal, affordable, and available without fraudulent coding.

Situation 2: Your BMI is below your state's threshold and you have no comorbidities

States that cover the obesity indication generally require BMI ≥30, or BMI ≥27 with comorbidities, and the sleep apnea pathways require BMI ≥30. If your BMI is 26 with no hypertension, diabetes, or dyslipidemia, your PA will be denied. Appealing won't change the outcome because you don't meet the clinical criteria.

Situation 3: You haven't tried behavioral weight loss and your state requires it

If your state's PA criteria require documented failure of diet and exercise for 90 days, and you started your first diet last week, your PA will be denied. Wait until you have 90 days of documented attempts, then submit.

Submitting a PA you know will be denied wastes your provider's time and starts the appeal clock prematurely.

Situation 4: You need treatment to start this week

Standard PA decisions can take up to 14 days under federal managed care rules. If you need to start treatment immediately (for example, pre-surgical weight loss with a scheduled surgery date), don't wait for Medicaid PA. Pay cash for one month or start compounded tirzepatide, then pursue the PA for ongoing coverage.

Situation 5: Your state covers liraglutide (Saxenda) without step therapy, and you haven't tried it

Some states cover the older GLP-1 liraglutide more readily than tirzepatide. If your state requires step therapy (try liraglutide first), and you haven't tried it, your Zepbound PA will be denied. Start with liraglutide, document response or intolerance, then request tirzepatide as second-line.

This is slower but has a higher approval rate than requesting tirzepatide first-line in a step-therapy state.

Medicare vs Medicaid in 2026: the GLP-1 Bridge and the BALANCE model

Two federal programs announced in 2026 are often confused with Medicaid coverage. Neither requires a state to cover Zepbound for obesity.

• Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027). Medicare Part D enrollees can obtain Wegovy (all forms), Zepbound KwikPen or Foundayo for a $50 monthly copay with prior authorization; the cost sits outside the $2,100 Part D out-of-pocket cap (KFF, May 11, 2026; healthinsurance.org, 2026). Zepbound vials and single-dose pens are not in the Bridge. This is Medicare, not Medicaid.
• CMS BALANCE model. Voluntary for state Medicaid programs, with rolling implementation from May 1, 2026 to January 1, 2027 and a state application deadline of July 31, 2026 (KFF, May 11, 2026). States that join negotiate GLP-1 pricing and may extend obesity coverage; states that do not join are unaffected.
• Dual eligibles. A person with both Medicare and Medicaid gets drug coverage through Part D, so the Bridge applies to them even in a state whose Medicaid program dropped the obesity benefit.

Self-pay reality check (dated)

If Medicaid will not cover Zepbound for obesity, these are the published cash options as of September 5, 2026:

• LillyDirect self-pay: $299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg through 15 mg per month, for vials or KwikPens, provided the refill is within 45 days of the prior fill; otherwise $499 to $699 (lilly.com/lillydirect/zepbound).
• Lilly savings card (commercial insurance only): $499 a month if the plan excludes Zepbound; as low as $25 with monthly caps of $100, $200 or $300 and an annual cap of $1,300 across 13 fills if the plan covers it, expiring December 31, 2026 (zepbound.lilly.com/coverage-savings). Medicaid and Medicare enrollees are not eligible.
• Compounded tirzepatide: no PA and no insurance, but not FDA approved. The FormBlends Compounded GLP-1 Price Index (September 3, 2026) shows a market median of $299 for month 1 across 14 vendors and $299 for month 4 across 11; FormBlends' own current price is on the product page and in the Compounded GLP-1 Price Index. The FDA reports more than 730 adverse event reports involving compounded tirzepatide as of May 31, 2026.

Correction, September 2026: an earlier version of this page quoted $1,060 to $1,350 for cash Zepbound and $179 to $279 (and, in one scenario, $229) for FormBlends compounded tirzepatide. Those figures were out of date and have been replaced with the dated prices above.

FAQ

Is Zepbound covered by Medicaid?

It depends on your state. KFF counted 13 state Medicaid fee-for-service programs covering GLP-1s for obesity as of January 2026, and Massachusetts left on July 1, 2026. Every state covers tirzepatide as Mounjaro for type 2 diabetes with prior authorization. Check your state's Medicaid preferred drug list to verify; an earlier version of this answer gave an 18/23/9 state split that was not sourced.

Which states cover Zepbound for weight loss on Medicaid?

KFF's January 2026 count is 13 fee-for-service programs, published as a map rather than a list, and it has changed since: California, New Hampshire, Pennsylvania (adults) and South Carolina ended coverage around January 1, 2026, Massachusetts on July 1, 2026, while North Carolina dropped it on October 1, 2025 and reinstated it in December 2025. An earlier version of this answer listed 18 states; that list was wrong and has been removed. Confirm with your state's preferred drug list.

Does Medicaid cover Zepbound in Texas?

We have not located a current Texas Medicaid bulletin covering Zepbound for obesity, and Texas is not described as a covering state in the sources we checked, but we could not verify the statutory exclusion an earlier version of this answer asserted. Texas Medicaid covers tirzepatide as Mounjaro for type 2 diabetes with prior authorization. Check the Texas Medicaid formulary for the current status, and see the self-pay options above if the obesity indication is not covered.

Does Medicaid cover Zepbound in Florida?

Florida is not among the states we could document as covering Zepbound for obesity, and Florida Medicaid covers tirzepatide as Mounjaro for type 2 diabetes with prior authorization, as every state does. We have not verified a Florida bulletin on the obesity indication, so confirm against the Florida Medicaid preferred drug list. Patients without diabetes in a non-covering state are left with self-pay options.

Does Medicaid cover Zepbound in California?

No, not for weight loss. Medi-Cal Rx announced on October 21, 2025 that effective January 1, 2026 it would no longer cover Saxenda, Wegovy or Zepbound when used for weight loss. Zepbound and other GLP-1s remain covered with prior authorization for FDA-approved uses such as type 2 diabetes, cardiovascular disease and kidney disease, and children can qualify under EPSDT. An earlier version of this answer said Medi-Cal covered Zepbound for weight management; that ended January 1, 2026.

What is the prior authorization process for Zepbound on Medicaid?

Your provider submits a PA form documenting your BMI, the qualifying diagnosis (in some states only sleep apnea qualifies), prior weight-loss attempts and medical necessity. Federal rules require a standard decision within 14 days (72 hours if expedited). If denied, you can appeal within the window your state sets, typically 30 to 60 days. No state publishes approval rates; a 34% figure that used to appear here had no source.

How much does Zepbound cost with Medicaid?

If your state covers Zepbound and your PA is approved, Medicaid copays are small or zero. If your state doesn't cover it or your PA is denied, Lilly's self-pay LillyDirect price as of September 5, 2026 is $299 (2.5 mg), $399 (5 mg) or $449 (7.5 mg and above) per month for vials or KwikPens refilled within 45 days, otherwise $499 to $699. An earlier version quoted a $1,060 to $1,350 cash price that is no longer accurate.

Can I get Zepbound on Medicaid if I have prediabetes?

In states that cover Zepbound for obesity, prediabetes is a weight-related comorbidity that can help meet a BMI 27-plus criterion. In states that cover tirzepatide only for type 2 diabetes (as Mounjaro), prediabetes alone does not qualify, because the covered indication is diabetes. Writing a diabetes diagnosis you do not have is fraud; a documented prediabetes diagnosis is not a diabetes diagnosis.

Does Medicaid cover compounded tirzepatide?

No. Medicaid does not cover compounded tirzepatide; it is paid out of pocket. Across 14 vendors tracked in the FormBlends Compounded GLP-1 Price Index on September 3, 2026, the median month-1 price was $299. FormBlends' current price is on the product page and in the index. Compounded tirzepatide is not FDA approved and, as of May 31, 2026, the FDA had received more than 730 adverse event reports involving it.

What happens if my Medicaid Zepbound prior authorization is denied?

You can appeal the denial within the window your state sets, typically 30 to 60 days. Your provider submits the documentation the denial letter asked for (a sleep study, dated weight history, diabetes exclusion). No source publishes a Zepbound appeal success rate; a 41% figure that used to appear here has been removed. If the appeal fails, alternatives include LillyDirect self-pay ($299 to $449 a month), compounded tirzepatide, or another covered medication.

Will Medicaid cover Zepbound in 2027?

It will keep varying by state, and the 2026 trend has been states dropping the benefit for budget reasons. The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973) addresses Medicare Part D, not Medicaid, and has not passed. CMS's BALANCE model (rolling from May 1, 2026 to January 1, 2027) is voluntary for states. No federal action pending as of September 5, 2026 would require Medicaid coverage of Zepbound for obesity.

Can my doctor prescribe Mounjaro instead of Zepbound to get Medicaid coverage?

Only if you have type 2 diabetes. Mounjaro and Zepbound contain the same drug (tirzepatide) but have different FDA-approved indications. Prescribing Mounjaro for a patient without diabetes solely to obtain Medicaid coverage is fraudulent. If you have diabetes or prediabetes, your doctor may legitimately prescribe tirzepatide for diabetes management.

Does Medicaid cover Zepbound in North Carolina?

NC Medicaid stopped covering Wegovy and Zepbound solely for obesity on October 1, 2025 while keeping coverage for other FDA-approved indications such as cardiovascular risk reduction, MASH and sleep apnea (NC Medicaid bulletin, November 4, 2025). KFF reports that North Carolina reinstated obesity coverage in December 2025. Prior authorization applies. Check the current NC Medicaid preferred drug list before assuming either status.

Does Medicaid cover Zepbound in Michigan?

Partly. Effective January 1, 2026, Michigan Medicaid reduced coverage of Wegovy, Zepbound and Saxenda when prescribed solely to treat obesity to narrower criteria, including morbid obesity and documented failure of alternatives, with the stated aim of avoiding bariatric surgery (Meridian provider bulletin, December 16, 2025). Prior authorizations approved before that date were honored for their 6-month term. Tirzepatide for type 2 diabetes (Mounjaro) remains covered.

Does Medicare cover Zepbound in 2026?

Through the Medicare GLP-1 Bridge, yes, for the KwikPen: from July 1, 2026 to December 31, 2027, Part D enrollees can get Zepbound KwikPen, Wegovy or Foundayo for a $50 monthly copay with prior authorization, and the cost does not count toward the $2,100 Part D cap (KFF, May 11, 2026; healthinsurance.org). This is a Medicare program and does not change any state Medicaid decision.

Related guides

• What Weight Loss Medication is Covered by Medicaid in 2026: State-by-State Coverage Rules
• Is Wegovy Covered by Medicaid in 2026? State-by-State Coverage Rules Explained
• Is Mounjaro Covered by Medicaid in 2026? State Rules, Prior Authorization, and What Happens When Coverage Is Denied
• Does Medicaid Cover Weight Loss Shots in 2026? State-by-State Coverage Rules
• Will Medicaid Pay for Ozempic in 2026? State-by-State Coverage Rules and What to Do If Denied
• Does Medicaid Pay for Ozempic in 2026? State-by-State Coverage Rules Explained
• Tool: cost calculator

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232. https://europepmc.org/article/MED/37952131
2. Centers for Medicare & Medicaid Services. Medicaid Managed Care Final Rule. Federal Register. 2024.
3. 42 U.S.C. § 1396r-8(d)(2). Medicaid Drug Rebate Program statute.
4. KFF. Medicaid Coverage of and Spending on GLP-1s, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
5. KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
6. Medi-Cal Rx (California DHCS). Important Update: GLP-1s for Weight Loss Not a Covered Benefit Effective January 1, 2026, bulletin dated October 21, 2025. https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/publications/2025.10_A_Important_Update_GLP-1s_Weight_Loss_Not_Covered_Benefit.pdf
7. Pennsylvania Health Law Project. PA Medicaid ends adult coverage of GLP-1s for weight loss, December 22, 2025. https://www.phlp.org/en/news/pa-medicaid-ends-adult-coverage-of-glp-1s-for-weight-loss
8. NC Medicaid. Updates to NC Medicaid coverage of Wegovy and Zepbound: clinical indications other than weight loss, November 4, 2025. https://medicaid.ncdhhs.gov/blog/2025/11/04/updates-nc-medicaid-coverage-wegovy-and-zepbound-clinical-indications-other-weight-loss
9. Meridian (Michigan Medicaid managed care). GLP-1 benefit reduction effective January 1, 2026, provider bulletin December 16, 2025. https://www.mimeridian.com/providers/bulletins/122025-glp1-benefit-reduction.html
10. West Virginia Bureau for Medical Services. Zepbound prior authorization criteria, effective July 1, 2025. https://bms.wv.gov/media/40699/download?inline
11. Louisiana Department of Health, Medicaid. Zepbound clinical criteria, June 5, 2025. https://ldh.la.gov/assets/medicaid/PharmPC/9_26_25/Zepbound.06052025.pdf
12. WBUR. Massachusetts cutting GLP-1 coverage in Medicaid for weight loss, June 23, 2026. https://www.wbur.org/news/2026/06/23/mass-cutting-glp-1-coverage-medicaid-wegovy-zepbound
13. 42 U.S.C. 1396r-8(d)(2)(A), Medicaid drug rebate statute (Omnibus Budget Reconciliation Act of 1990). https://www.law.cornell.edu/uscode/text/42/1396r-8
14. Nasdaq (Quiver Quantitative). Representative Mike Kelly introduces H.R. 4231, Treat and Reduce Obesity Act of 2025, June 27, 2025. https://www.nasdaq.com/articles/new-bill-representative-mike-kelly-introduces-hr-4231-treat-and-reduce-obesity-act-2025
15. Congressional Budget Office. How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget? Publication 60441, October 2024 (cbo.gov; not linked because the site blocks automated access).
16. Eli Lilly and Company. Zepbound coverage and savings (2026 savings card terms). https://zepbound.lilly.com/coverage-savings
17. Eli Lilly and Company. LillyDirect Zepbound self-pay pricing. https://www.lilly.com/lillydirect/zepbound
18. healthinsurance.org. Does health insurance cover drugs used for weight loss such as Ozempic, Wegovy, Mounjaro and Zepbound? (Medicare GLP-1 Bridge terms), 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
19. FormBlends. Compounded GLP-1 Price Index data feed, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json
20. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of September 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk A/S. Medicaid is a registered service mark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.